Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN
NCT06589752
·
clinicaltrials.gov ↗
COMPLETED
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Primary IgA Nephropathy
Interventions
DRUG:
TARPEYO 4 MG Delayed Release Oral Capsule
DRUG:
RAS inhibitor
Sponsor
Ruijin Hospital